Figure 5.
SAR442085 antibody trigger higher ADCC by MM patients' NK cells. (A-F) NK cells purified from the bone marrow of newly diagnosed MM patients were cocultured with RPMI-8226 MM cell line in the presence of daratumumab, SAR442085, or isotype control (700 pM). (A) Experimental design. (B) FACS histograms and graph showing the NK cell changes in FcγRIIIa expression as compared with Ig control in the presence of the indicated mAbs at 70 pM. (C) Relative decrease in FcγRIIIa expression as compared with Ig control induced by increasing dose of the indicated mAbs (mean ± SEM of 15 MM patients). (D) FACS histograms and graph showing the NK cell CD107a expression in the presence of the indicated mAbs at 70 pM. (E) CD107a expressing NKs with increasing dose of the indicated mAbs (mean ± SEM of 15 MM patients). (F) NK cell FcγRIIIa decrease induced by the indicated mAbs at 70 pM according to the FcγRIIIa-158 V or F genotype of the MM patients. (G-K) NK cells purified from the bone marrow of newly diagnosed MM patients were cocultured with MM patients’ CD138+ plasma cells preincubated with increasing concentrations of SAR442085, daratumumab, or isotype control (700 pM). (G) Experimental design. (H) FACS histograms and graph showing the NK cell changes in FcγRIIIa expression as compared with Ig control in the presence of the indicated mAbs at 70 pM. (I) Relative decrease in FcγRIIIa expression as compared with Ig control induced by increasing dose of the indicated mAbs (mean ± SEM of 12 MM patients). (J) FACS plots and graph showing the NK cell CD107a expression in the presence of the indicated mAbs at 70 pM. (K) CD107a expressing NKs with increasing dose of the indicated mAbs (mean ± SEM of 11 MM patients). Statistical differences between SAR442085 and daratumumab groups were determined by a two-way ANOVA with Bonferroni-Holm correction. *P < .05, **P < .01, ***P < .001.

SAR442085 antibody trigger higher ADCC by MM patients' NK cells. (A-F) NK cells purified from the bone marrow of newly diagnosed MM patients were cocultured with RPMI-8226 MM cell line in the presence of daratumumab, SAR442085, or isotype control (700 pM). (A) Experimental design. (B) FACS histograms and graph showing the NK cell changes in FcγRIIIa expression as compared with Ig control in the presence of the indicated mAbs at 70 pM. (C) Relative decrease in FcγRIIIa expression as compared with Ig control induced by increasing dose of the indicated mAbs (mean ± SEM of 15 MM patients). (D) FACS histograms and graph showing the NK cell CD107a expression in the presence of the indicated mAbs at 70 pM. (E) CD107a expressing NKs with increasing dose of the indicated mAbs (mean ± SEM of 15 MM patients). (F) NK cell FcγRIIIa decrease induced by the indicated mAbs at 70 pM according to the FcγRIIIa-158 V or F genotype of the MM patients. (G-K) NK cells purified from the bone marrow of newly diagnosed MM patients were cocultured with MM patients’ CD138+ plasma cells preincubated with increasing concentrations of SAR442085, daratumumab, or isotype control (700 pM). (G) Experimental design. (H) FACS histograms and graph showing the NK cell changes in FcγRIIIa expression as compared with Ig control in the presence of the indicated mAbs at 70 pM. (I) Relative decrease in FcγRIIIa expression as compared with Ig control induced by increasing dose of the indicated mAbs (mean ± SEM of 12 MM patients). (J) FACS plots and graph showing the NK cell CD107a expression in the presence of the indicated mAbs at 70 pM. (K) CD107a expressing NKs with increasing dose of the indicated mAbs (mean ± SEM of 11 MM patients). Statistical differences between SAR442085 and daratumumab groups were determined by a two-way ANOVA with Bonferroni-Holm correction. *P < .05, **P < .01, ***P < .001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal